| pubmed-article:11953965 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11953965 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:11953965 | lifeskim:mentions | umls-concept:C0003873 | lld:lifeskim |
| pubmed-article:11953965 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:11953965 | lifeskim:mentions | umls-concept:C0022417 | lld:lifeskim |
| pubmed-article:11953965 | lifeskim:mentions | umls-concept:C0001721 | lld:lifeskim |
| pubmed-article:11953965 | lifeskim:mentions | umls-concept:C0449258 | lld:lifeskim |
| pubmed-article:11953965 | lifeskim:mentions | umls-concept:C1550594 | lld:lifeskim |
| pubmed-article:11953965 | lifeskim:mentions | umls-concept:C0312653 | lld:lifeskim |
| pubmed-article:11953965 | lifeskim:mentions | umls-concept:C0004083 | lld:lifeskim |
| pubmed-article:11953965 | lifeskim:mentions | umls-concept:C1548760 | lld:lifeskim |
| pubmed-article:11953965 | lifeskim:mentions | umls-concept:C1547300 | lld:lifeskim |
| pubmed-article:11953965 | lifeskim:mentions | umls-concept:C0580822 | lld:lifeskim |
| pubmed-article:11953965 | lifeskim:mentions | umls-concept:C1883709 | lld:lifeskim |
| pubmed-article:11953965 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:11953965 | pubmed:dateCreated | 2002-4-15 | lld:pubmed |
| pubmed-article:11953965 | pubmed:abstractText | The presence of certain HLA class II antigens is strongly associated with the progression of joint destruction in rheumatoid arthritis (RA). Such antigens may be more effective than other class II antigens in inducing the formation of autoreactive T cells after presentation of (auto)antigens. We investigated whether early and aggressive treatment with disease-modifying antirheumatic drugs could modify this relationship. | lld:pubmed |
| pubmed-article:11953965 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11953965 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11953965 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11953965 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:11953965 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11953965 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11953965 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11953965 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:11953965 | pubmed:issn | 0004-3591 | lld:pubmed |
| pubmed-article:11953965 | pubmed:author | pubmed-author:BoeroAA | lld:pubmed |
| pubmed-article:11953965 | pubmed:author | pubmed-author:VissetJJ | lld:pubmed |
| pubmed-article:11953965 | pubmed:author | pubmed-author:ZanellaMM | lld:pubmed |
| pubmed-article:11953965 | pubmed:author | pubmed-author:VerhoevenAA | lld:pubmed |
| pubmed-article:11953965 | pubmed:author | pubmed-author:BreedveldF... | lld:pubmed |
| pubmed-article:11953965 | pubmed:author | pubmed-author:ZwindermanA... | lld:pubmed |
| pubmed-article:11953965 | pubmed:author | pubmed-author:ORUEJJ | lld:pubmed |
| pubmed-article:11953965 | pubmed:author | pubmed-author:van der... | lld:pubmed |
| pubmed-article:11953965 | pubmed:author | pubmed-author:VosKK | lld:pubmed |
| pubmed-article:11953965 | pubmed:author | pubmed-author:HazesJ M WJM | lld:pubmed |
| pubmed-article:11953965 | pubmed:author | pubmed-author:HuizingaT W... | lld:pubmed |
| pubmed-article:11953965 | pubmed:author | pubmed-author:SchreuderG... | lld:pubmed |
| pubmed-article:11953965 | pubmed:author | pubmed-author:De VriesR R... | lld:pubmed |
| pubmed-article:11953965 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11953965 | pubmed:volume | 46 | lld:pubmed |
| pubmed-article:11953965 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11953965 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11953965 | pubmed:pagination | 899-905 | lld:pubmed |
| pubmed-article:11953965 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:11953965 | pubmed:meshHeading | pubmed-meshheading:11953965... | lld:pubmed |
| pubmed-article:11953965 | pubmed:meshHeading | pubmed-meshheading:11953965... | lld:pubmed |
| pubmed-article:11953965 | pubmed:meshHeading | pubmed-meshheading:11953965... | lld:pubmed |
| pubmed-article:11953965 | pubmed:meshHeading | pubmed-meshheading:11953965... | lld:pubmed |
| pubmed-article:11953965 | pubmed:meshHeading | pubmed-meshheading:11953965... | lld:pubmed |
| pubmed-article:11953965 | pubmed:meshHeading | pubmed-meshheading:11953965... | lld:pubmed |
| pubmed-article:11953965 | pubmed:meshHeading | pubmed-meshheading:11953965... | lld:pubmed |
| pubmed-article:11953965 | pubmed:meshHeading | pubmed-meshheading:11953965... | lld:pubmed |
| pubmed-article:11953965 | pubmed:meshHeading | pubmed-meshheading:11953965... | lld:pubmed |
| pubmed-article:11953965 | pubmed:meshHeading | pubmed-meshheading:11953965... | lld:pubmed |
| pubmed-article:11953965 | pubmed:meshHeading | pubmed-meshheading:11953965... | lld:pubmed |
| pubmed-article:11953965 | pubmed:meshHeading | pubmed-meshheading:11953965... | lld:pubmed |
| pubmed-article:11953965 | pubmed:meshHeading | pubmed-meshheading:11953965... | lld:pubmed |
| pubmed-article:11953965 | pubmed:meshHeading | pubmed-meshheading:11953965... | lld:pubmed |
| pubmed-article:11953965 | pubmed:meshHeading | pubmed-meshheading:11953965... | lld:pubmed |
| pubmed-article:11953965 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:11953965 | pubmed:articleTitle | Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage. | lld:pubmed |
| pubmed-article:11953965 | pubmed:affiliation | Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands. l.r.lard@lumc.nl | lld:pubmed |
| pubmed-article:11953965 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11953965 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11953965 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11953965 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11953965 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11953965 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11953965 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11953965 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11953965 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11953965 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11953965 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11953965 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11953965 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11953965 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11953965 | lld:pubmed |
